DELIVER Delivers for AZ; Priority Review Depends on CV Death
AstraZeneca announced top-line results from the Ph3 DELIVER trial (view CT.gov record) demonstrating AZ’s Farxiga (dapagliflozin) has met the primary composite endpoint of CV death or worsening HF in HFpEF subjects. Below, FENIX provides initial thoughts.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.